» interventional cardiology | drug-eluting stent

Adjust Font Size:

The MiStent^® SES is a CE Marked drug-eluting stent that has been designed to optimize healing. Read more. Please visit our Events page for a listing of publications and recent conference presentations.		Nov 3, 2014 — Micell Technologies Announces Plans for MiStent SES® Commercial Launch Read more. Sep 16, 2014 — Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014 Read more.		Micell Technologies is bringing together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent. The resulting drug-delivery device is intended to redefine the field of interventional cardiology. Read more. Micell published in the October 2013 issue of JACC Cardiovascular Interventions. Read more.. Micell published in the Journal of Controlled Release on the enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. Read more.


Caution: The MiStent SES has received CE marking but is not approved in the USA or any other countries. Any other products described on this website are investigational devices that are not available for sale in any country. Home \| About Us \| Therapeutic Focus \| Product Pipeline \| Technology \| News \| Terms of Use \| Privacy Policy \| Site Map		© 2015 Micell Technologies, Inc. All rights reserved. "Micell", "MiStent", and "MiStent SES" are registered trademarks of Micell Technologies, Inc.